Checkpoint Agrees To Sun Pharma Buyout

Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
Sun Pharma agrees to acquire Checkpoint Therapeutics
Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, for $355 million. The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations.
Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. | Takeda is sharpening its oncology focus amid an R&D revamp.
Sun Pharma Acquires Checkpoint Therapeutics for $355 Million
Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma.
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
India's pharma giant Sun Pharma to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment of $355M. The deal involves an upfront cash payment of $4.
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLOXCYT,
Fierce Pharma4d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
Sun Pharma is betting big on speciality. Will it pay off?
Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
Sun Pharma to Acquire Checkpoint Therapeutics
(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...